Efficacy and safety of ibopamine in congestive heart failure

D. J. Van Veldhuisen; A. R.J. Girbes; K. I. Lie

Efficacy and safety of ibopamine in congestive heart failure

D. J. Van Veldhuisen, A. R.J. Girbes, K. I. Lie

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Abstract

The oral dopamine agonist, ibopamine, has beneficial cardiovascular, renal, and neuroendocrine effects. It is generally well tolerated by patient with congestive heart failure (CHF). Furthermore, the drug appears to be safe. Ibopamine may be used as an adjunct to therapy with digoxin, diuretics, and angiotensin-converting enzyme inhibitors for patients with advanced CHF, or as an alternative in those who do not tolerate these drugs. Research suggests that ibopamine may, be used as first-line therapy for early CHF, and it may be given to patients who are dopamine-dependent.

Original language	English
Pages (from-to)	21-26+52
Journal	Primary Cardiology
Volume	20
Issue number	12
Publication status	Published - 1 Jan 1994

Cite this

@article{a6cc7fdfd55248099e8d24b83f44691c,

title = "Efficacy and safety of ibopamine in congestive heart failure",

abstract = "The oral dopamine agonist, ibopamine, has beneficial cardiovascular, renal, and neuroendocrine effects. It is generally well tolerated by patient with congestive heart failure (CHF). Furthermore, the drug appears to be safe. Ibopamine may be used as an adjunct to therapy with digoxin, diuretics, and angiotensin-converting enzyme inhibitors for patients with advanced CHF, or as an alternative in those who do not tolerate these drugs. Research suggests that ibopamine may, be used as first-line therapy for early CHF, and it may be given to patients who are dopamine-dependent.",

author = "{Van Veldhuisen}, {D. J.} and Girbes, {A. R.J.} and Lie, {K. I.}",

year = "1994",

month = jan,

day = "1",

language = "English",

volume = "20",

pages = "21--26+52",

journal = "Primary Cardiology",

issn = "0363-5104",

number = "12",

}

TY - JOUR

T1 - Efficacy and safety of ibopamine in congestive heart failure

AU - Van Veldhuisen, D. J.

AU - Girbes, A. R.J.

AU - Lie, K. I.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The oral dopamine agonist, ibopamine, has beneficial cardiovascular, renal, and neuroendocrine effects. It is generally well tolerated by patient with congestive heart failure (CHF). Furthermore, the drug appears to be safe. Ibopamine may be used as an adjunct to therapy with digoxin, diuretics, and angiotensin-converting enzyme inhibitors for patients with advanced CHF, or as an alternative in those who do not tolerate these drugs. Research suggests that ibopamine may, be used as first-line therapy for early CHF, and it may be given to patients who are dopamine-dependent.

AB - The oral dopamine agonist, ibopamine, has beneficial cardiovascular, renal, and neuroendocrine effects. It is generally well tolerated by patient with congestive heart failure (CHF). Furthermore, the drug appears to be safe. Ibopamine may be used as an adjunct to therapy with digoxin, diuretics, and angiotensin-converting enzyme inhibitors for patients with advanced CHF, or as an alternative in those who do not tolerate these drugs. Research suggests that ibopamine may, be used as first-line therapy for early CHF, and it may be given to patients who are dopamine-dependent.

UR - http://www.scopus.com/inward/record.url?scp=0028061324&partnerID=8YFLogxK

M3 - Article

SN - 0363-5104

VL - 20

SP - 21-26+52

JO - Primary Cardiology

JF - Primary Cardiology

IS - 12

ER -

Efficacy and safety of ibopamine in congestive heart failure

Abstract

Other files and links

Cite this